La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Akeso Crescita futura

Future criteri di controllo 2/6

Akeso prevede che gli utili e i ricavi cresceranno rispettivamente di 7.2% e 18.3% all'anno. Si prevede che l'EPS diminuirà di 1.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 19.7% in 3 anni.

Informazioni chiave

7.2%

Tasso di crescita degli utili

-1.8%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.4%
Tasso di crescita dei ricavi	18.3%
Rendimento futuro del capitale proprio	19.7%
Copertura analitica	Good
Ultimo aggiornamento	19 Aug 2024

Aggiornamenti recenti sulla crescita futura

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Recent updates

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 24

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Jun 19

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Mar 20

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Dec 28

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Nov 16

Is Akeso (HKG:9926) Using Too Much Debt?

Oct 02

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Aug 31

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Jun 26

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

May 22

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Apr 11

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Mar 21

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Mar 02

Akeso, Inc.'s (HKG:9926) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

Time To Worry? Analysts Are Downgrading Their Akeso, Inc. (HKG:9926) Outlook

Aug 28

Is Akeso (HKG:9926) Using Too Much Debt?

Apr 10

Previsioni di crescita degli utili e dei ricavi

SEHK:9926 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	6,104	1,189	1,259	1,594	22
12/31/2025	4,086	210	-57	303	22
12/31/2024	2,598	-403	-701	-105	22
12/31/2023	4,526	2,028	1,588	2,468	N/A
9/30/2023	4,439	2,008	1,459	2,340	N/A
6/30/2023	4,351	1,987	1,330	2,212	N/A
3/31/2023	2,595	409	-356	486	N/A
12/31/2022	838	-1,168	-2,043	-1,240	N/A
9/30/2022	549	-1,224	-1,997	-1,238	N/A
6/30/2022	260	-1,280	-1,952	-1,235	N/A
3/31/2022	243	-1,178	-1,835	-1,118	N/A
12/31/2021	226	-1,075	-1,717	-1,001	N/A
9/30/2021	177	-1,002	-1,525	-882	N/A
6/30/2021	129	-929	-1,333	-762	N/A
3/31/2021	64	-983	-1,200	-690	N/A
12/31/2020	N/A	-1,036	-1,066	-618	N/A
9/30/2020	35	-870	-814	-443	N/A
6/30/2020	71	-703	-562	-267	N/A
3/31/2020	71	-492	-459	-243	N/A
12/31/2019	71	-282	-356	-220	N/A
12/31/2018	3	-142	-198	-123	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 9926 ( 7.2% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 9926 ( 7.2% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 9926 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 9926 ( 18.3% all'anno) crescerà più rapidamente del mercato Hong Kong ( 7.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 9926 ( 18.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 9926 sarà basso tra 3 anni ( 19.7 %).

Akeso Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

Forecast to breakeven in 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

Forecast to breakeven in 2024

Recent updates

Akeso, Inc. to Report Q2, 2024 Results on Aug 28, 2024

Akeso, Inc. Announces Ivonescimab (Pd-1/Vegf) Received Priority Review from China's Nmpa for First-Line Treatment of Pd-L1 Positive Nsclc

Akeso, Inc. Announces That the First Patient Enrolled in the US Phase 2 Combination Therapy of it's Ligufalimab with Azacitidine for Myelodysplastic Syndrome

Akeso's Sbla for Ivonescimab in 1L Treatment of Pd-L1 Positive Nsclc Accepted by NMPA

Akeso, Inc. Announces Appointment of Bing C. Wang as Chief Financial Officer

New major risk - Share price stability

Akeso, Inc. Announces Change of Directors

Akeso, Inc.'s (HKG:9926) CEO Compensation Is Looking A Bit Stretched At The Moment

Little Excitement Around Akeso, Inc.'s (HKG:9926) Revenues As Shares Take 25% Pounding

Akeso, Inc., Annual General Meeting, Jun 30, 2024

Akeso, Inc. Announces Phase III Clinical Trial, Harmoni-2 or AK112-303 Met Its Primary Endpoint of Progression-Free Survival

Are Investors Undervaluing Akeso, Inc. (HKG:9926) By 43%?

New minor risk - Share price stability

Akeso, Inc. Receives NMPA's Marketing Approval in China for Ivonescimab Injection

Investor sentiment deteriorates as stock falls 24%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

We Think Akeso's (HKG:9926) Robust Earnings Are Conservative

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Results: Akeso, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Insufficient Growth At Akeso, Inc. (HKG:9926) Hampers Share Price

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 34% Undervalued

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Is Akeso (HKG:9926) Using Too Much Debt?

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

The Akeso, Inc. (HKG:9926) Half-Yearly Results Are Out And Analysts Have Published New Forecasts

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Is Akeso, Inc. (HKG:9926) Trading At A 40% Discount?

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

There's Reason For Concern Over Akeso, Inc.'s (HKG:9926) Price

Health Check: How Prudently Does Akeso (HKG:9926) Use Debt?

Growth Investors: Industry Analysts Just Upgraded Their Akeso, Inc. (HKG:9926) Revenue Forecasts By 18%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2023

An Intrinsic Calculation For Akeso, Inc. (HKG:9926) Suggests It's 49% Undervalued

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Now 24% undervalued

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

Less than half of directors are independent